Trilostane monitoring in canine hyperadrenocorticism: can basal cortisol replace the ACTH stimulation test?

Dr Tsouloufi, Ioannis L Oikonomidis
{"title":"Trilostane monitoring in canine hyperadrenocorticism: can basal cortisol replace the ACTH stimulation test?","authors":"Dr Tsouloufi, Ioannis L Oikonomidis","doi":"10.18849/ve.v6i3.412","DOIUrl":null,"url":null,"abstract":"PICO question \nIn dogs with hyperadrenocorticism that are being treated with trilostane, does the measurement of basal cortisol levels have comparable diagnostic performance to the adrenocorticotropic hormone (ACTH) stimulation test? \n  \nClinical bottom line \nCategory of research question \nDiagnosis (effectiveness of treatment monitoring) \nThe number and type of study designs reviewed \nFour cross-sectional diagnostic accuracy studies were critically reviewed \nStrength of evidence \nWeak to moderate (level 2) \nOutcomes reported \nThere is evidence of moderate strength suggesting that basal cortisol measured at 4–6 hours (and possibly 2–3 hours) post-trilostane can be a good test to exclude adrenal oversuppression, while its use is not suggested for diagnostic confirmation of oversuppression. There is evidence of weak strength that basal cortisol might be helpful for identifying dogs with inadequate adrenal suppression, but cannot be used to rule it out \nConclusion \nAlthough the evaluation of the available evidence is difficult due to its heterogeneity, there is moderate evidence that a basal cortisol measured at 4–6 hours (and possibly 2–3 hours) post-trilostane dose can be a good test to rule out adrenal oversuppression, but that it cannot be used to definitively diagnose oversuppression. The current evidence suggests that basal cortisol is less useful for identification of inadequate control. Based on one included study, neither ACTH-stimulated nor basal cortisol levels correlate optimally with the actual clinical response of the patient. In this context, it can be concluded that none of the currently used laboratory tests should be used as a sole monitoring tool in dogs with hyperadrenocorticism receiving trilostane and thus, the assessment of the clinical response is of utmost importance \n  \nHow to apply this evidence in practice \nThe application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. \nKnowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.","PeriodicalId":257905,"journal":{"name":"Veterinary Evidence","volume":"16 5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary Evidence","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18849/ve.v6i3.412","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

PICO question In dogs with hyperadrenocorticism that are being treated with trilostane, does the measurement of basal cortisol levels have comparable diagnostic performance to the adrenocorticotropic hormone (ACTH) stimulation test?   Clinical bottom line Category of research question Diagnosis (effectiveness of treatment monitoring) The number and type of study designs reviewed Four cross-sectional diagnostic accuracy studies were critically reviewed Strength of evidence Weak to moderate (level 2) Outcomes reported There is evidence of moderate strength suggesting that basal cortisol measured at 4–6 hours (and possibly 2–3 hours) post-trilostane can be a good test to exclude adrenal oversuppression, while its use is not suggested for diagnostic confirmation of oversuppression. There is evidence of weak strength that basal cortisol might be helpful for identifying dogs with inadequate adrenal suppression, but cannot be used to rule it out Conclusion Although the evaluation of the available evidence is difficult due to its heterogeneity, there is moderate evidence that a basal cortisol measured at 4–6 hours (and possibly 2–3 hours) post-trilostane dose can be a good test to rule out adrenal oversuppression, but that it cannot be used to definitively diagnose oversuppression. The current evidence suggests that basal cortisol is less useful for identification of inadequate control. Based on one included study, neither ACTH-stimulated nor basal cortisol levels correlate optimally with the actual clinical response of the patient. In this context, it can be concluded that none of the currently used laboratory tests should be used as a sole monitoring tool in dogs with hyperadrenocorticism receiving trilostane and thus, the assessment of the clinical response is of utmost importance   How to apply this evidence in practice The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources. Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.
犬肾上腺皮质亢进的trilostine监测:基础皮质醇能代替ACTH刺激试验吗?
PICO问题:在接受三叶甾烷治疗的肾上腺皮质亢进犬中,测量基础皮质醇水平是否与促肾上腺皮质激素(ACTH)刺激试验具有可比性的诊断性能?临床底线研究问题类别诊断(治疗监测的有效性)研究设计的数量和类型被审查了四个横断诊断准确性研究的严格审查证据强度弱到中等(2级)报道的结果有中等强度的证据表明,在使用三叶烷后4-6小时(也可能是2 - 3小时)测量基础皮质醇可以是排除肾上腺过度抑制的良好测试。但不建议用于过度抑制的诊断确认。有微弱的证据表明,基础皮质醇可能有助于识别肾上腺抑制不足的狗,但不能用于排除。结论尽管由于其异质性,对现有证据的评估很困难,但有适度的证据表明,在三叶甾烷给药后4-6小时(也可能是2-3小时)测量基础皮质醇可以很好地排除肾上腺过度抑制。但它不能用于明确诊断过度抑制。目前的证据表明,基础皮质醇在识别控制不足方面用处不大。根据一项纳入的研究,acth刺激和基础皮质醇水平与患者的实际临床反应都没有最佳相关性。在这种情况下,可以得出结论,目前使用的实验室测试都不应作为接受trilostane治疗的肾上腺皮质亢进犬的唯一监测工具,因此,对临床反应的评估至关重要。如何将这些证据应用于实践。证据应用于实践应考虑多种因素,不限于:个人的临床专业知识,病人的情况和业主的价值观,你工作的国家,地点或诊所,你面前的个案,治疗和资源的可用性。知识摘要是帮助加强或告知决策的资源。他们不会凌驾于从业者的责任或判断之上,去做对他们照顾的动物最好的事情。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信